US Therapeutic Plasma Exchange Market - Forecast to 2025

Table of Content

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.2.1 INCLUSIONS AND EXCLUSIONS 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 20
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 20
1.7 SUMMARY OF CHANGES 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
FIGURE 1 RESEARCH DESIGN 22
2.1.1 SECONDARY DATA 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY DATA 24
FIGURE 2 PRIMARY SOURCES 24
2.1.2.1 Key data from primary sources 25
2.1.2.2 Breakdown of primary interviews 25
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY
TYPE AND DESIGNATION 25
2.2 MARKET SIZE ESTIMATION 26
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 26
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (ILLUSTRATIVE EXAMPLE) 27
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 28
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 30
FIGURE 7 DATA TRIANGULATION METHODOLOGY 30
2.4 MARKET SHARE ESTIMATION 31
2.5 ASSUMPTIONS FOR THE STUDY 31

3 EXECUTIVE SUMMARY 32
FIGURE 8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 32
FIGURE 9 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY,
2020 VS. 2025 (USD MILLION) 33
FIGURE 10 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION,
2020 VS. 2025 (USD MILLION) 33
FIGURE 11 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 34

4 MARKET OVERVIEW 35
4.1 INTRODUCTION 35
4.2 MARKET DYNAMICS 35
FIGURE 12 US THERAPEUTIC PLASMA EXCHANGE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
4.2.1 DRIVERS 36
4.2.1.1 Rising prevalence of chronic diseases 36
4.2.1.2 Technological advancements 36
4.2.2 RESTRAINTS 37
4.2.2.1 High cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model 37
4.2.3 OPPORTUNITIES 37
4.2.3.1 Therapeutic plasma exchange for pediatric patients 37
4.2.4 CHALLENGES 38
4.2.4.1 Dearth of skilled professionals 38

5 INDUSTRY INSIGHTS 39
5.1 INDUSTRY TRENDS 39
5.1.1 IMPACT OF COVID-19 ON THE THERAPEUTIC PLASMA EXCHANGE MARKET 39
FIGURE 13 IMPACT OF COVID-19 (2020-2025) 40
5.1.2 NEW INDICATIONS FOR PLASMA PRODUCTS 40
5.2 PORTER’S FIVE FORCES ANALYSIS 41
FIGURE 14 PORTER’S FIVE FORCES ANALYSIS (2019): US THERAPEUTIC PLASMA EXCHANGE MARKET 41
5.2.1 THREAT OF NEW ENTRANTS 42
5.2.2 THREAT OF SUBSTITUTES 42
5.2.3 BARGAINING POWER OF SUPPLIERS 42
5.2.4 BARGAINING POWER OF BUYERS 43
5.2.5 RIVALRY AMONG EXISTING COMPETITORS 43
5.3 VALUE CHAIN ANALYSIS 43
FIGURE 15 VALUE CHAIN: US THERAPEUTIC PLASMA EXCHANGE MARKET 44
5.4 REGULATORY ANALYSIS 45
5.4.1 US 45
?

6 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT & TECHNOLOGY 46
6.1 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT 47
6.1.1 INTRODUCTION 47
TABLE 2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 47
6.1.2 CONSUMABLES 47
6.1.2.1 Recurrent use of consumables to drive the growth of this segment 47
6.1.3 DEVICES 48
6.1.3.1 Increasing installation of devices in hospitals for therapeutic plasma exchange to drive market growth 48
6.2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY 49
6.2.1 INTRODUCTION 49
TABLE 3 CENTRIFUGATION VS. MEMBRANE SEPARATION 49
FIGURE 16 CENTRIFUGATION SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD 49
TABLE 4 THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 50
6.2.2 CENTRIFUGATION 50
6.2.2.1 Centrifugation technology to dominate the US therapeutic plasma exchange market 50
TABLE 5 KEY PRODUCTS OFFERED IN THE CENTRIFUGATION MARKET 50
6.2.3 MEMBRANE SEPARATION 51
6.2.3.1 Recent advances in developing highly permeable filters are supporting the growth of this market 51
TABLE 6 SIZE OF BLOOD COMPONENTS 51
TABLE 7 MEMBRANE SEPARATION PRODUCTS AVAILABLE IN THE MARKET 52

7 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION 53
7.1 INTRODUCTION 54
7.2 NEUROLOGICAL DISORDERS 54
7.2.1 NEUROLOGICAL DISORDERS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019 54
TABLE 8 NEUROLOGICAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 54
7.2.1.1 Guillain–Barr? syndrome 55
7.2.1.1.1 Patient and procedure data for guillain-barr? syndrome 55
TABLE 9 DISEASE STATISTICS: GUILLAIN-BARR? SYNDROME 55
TABLE 10 TREATMENT GUIDELINES AND PROTOCOLS FOR GUILLAIN-BARR? SYNDROME 55
TABLE 11 EPIDEMIOLOGY FOR GUILLAIN-BARR? SYNDROME 56
7.2.1.2 Chronic inflammatory demyelinating polyneuropathy 56
7.2.1.2.1 Patient and procedure data for chronic inflammatory demyelinating polyneuropathy 56
TABLE 12 DISEASE STATISTICS: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY 56
TABLE 13 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY 57
TABLE 14 EPIDEMIOLOGY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY 57
7.2.1.3 Myasthenia gravis 57
7.2.1.3.1 Patient and procedure data for myasthenia gravis 58
TABLE 15 DISEASE STATISTICS: MYASTHENIA GRAVIS 58
TABLE 16 TREATMENT GUIDELINES AND PROTOCOLS FOR MYASTHENIA GRAVIS 58
TABLE 17 EPIDEMIOLOGY FOR MYASTHENIA GRAVIS 59
7.2.1.4 Multiple sclerosis 59
7.2.1.4.1 Patient and procedure data for multiple sclerosis 59
TABLE 18 DISEASE STATISTICS: MULTIPLE SCLEROSIS 59
TABLE 19 TREATMENT GUIDELINES AND PROTOCOLS FOR MULTIPLE SCLEROSIS 60
TABLE 20 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS 60
TABLE 21 EPIDEMIOLOGY FOR MULTIPLE SCLEROSIS 60
7.2.1.5 PANDAS 61
7.2.1.5.1 Patient and procedure data for PANDAS 61
TABLE 22 DISEASE STATISTICS: PANDAS 61
TABLE 23 TREATMENT GUIDELINES AND PROTOCOLS FOR PANDAS 61
TABLE 24 EPIDEMIOLOGY FOR PANDAS 62
7.3 HEMATOLOGIC DISORDERS 62
7.3.1 INCREASING PREVALENCE AND INCIDENCE OF HEMATOLOGIC DISORDERS WILL BOOST THE DEMAND FOR THERAPEUTIC PLASMA EXCHANGE 62
TABLE 25 HEMATOLOGIC DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 62
7.3.1.1 Thrombotic thrombocytopenic purpura 62
7.3.1.1.1 Patient and procedure data for thrombotic thrombocytopenic purpura 63
TABLE 26 DISEASE STATISTICS: THROMBOTIC THROMBOCYTOPENIC PURPURA 63
TABLE 27 TREATMENT GUIDELINES AND PROTOCOLS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA 63
TABLE 28 EPIDEMIOLOGY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA 63
7.3.1.2 Atypical hemolytic uremic syndrome 64
7.3.1.2.1 Patient and procedure data for atypical hemolytic uremic syndrome 64
TABLE 29 DISEASE STATISTICS: ATYPICAL HEMOLYTIC UREMIC SYNDROME 64
TABLE 30 TREATMENT GUIDELINES AND PROTOCOL FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME 65
TABLE 31 EPIDEMIOLOGY FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME 65
7.3.1.3 Hyperviscosity syndrome 65
7.3.1.3.1 Patient and procedure data for hyperviscosity syndrome 66
TABLE 32 DISEASE STATISTICS: HYPERVISCOSITY SYNDROME 66
TABLE 33 TREATMENT GUIDELINES AND PROTOCOLS FOR HYPERVISCOSITY SYNDROME 66
TABLE 34 EPIDEMIOLOGY FOR HYPERVISCOSITY SYNDROME 66
7.3.1.4 Severe/symptomatic cryoglobulinemia 67
7.3.1.4.1 Patient and procedure data for cryoglobulinemia 67
TABLE 35 DISEASE STATISTICS: CRYOGLOBULINEMIA 67
TABLE 36 TREATMENT GUIDELINES AND PROTOCOLS FOR CRYOGLOBULINEMIA 67
TABLE 37 EPIDEMIOLOGY FOR CRYOGLOBULINEMIA 68
7.4 RENAL DISORDERS 68
7.4.1 THERAPEUTIC PLASMA EXCHANGE IS REGARDED AS ONE OF THE MOST USEFUL TREATMENT OPTIONS FOR SEVERAL RENAL DISORDERS 68
TABLE 38 RENAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 68
7.4.1.1 Goodpasture syndrome 69
7.4.1.1.1 Patient and procedure data for goodpasture syndrome 69
TABLE 39 DISEASE STATISTICS: GOODPASTURE SYNDROME 69
TABLE 40 TREATMENT GUIDELINES AND PROTOCOLS FOR GOODPASTURE SYNDROME 69
TABLE 41 EPIDEMIOLOGY FOR GOODPASTURE SYNDROME 70
7.4.1.2 WEGENER’S GRANULOMATOSIS (ANCA)-associated rapidly progressive glomerulonephritis 70
7.4.1.2.1 Patient and procedure data for wegener’s granulomatosis 70
TABLE 42 DISEASE STATISTICS: WEGENER’S GRANULOMATOSIS 70
TABLE 43 TREATMENT GUIDELINES AND PROTOCOLS FOR WEGENER’S GRANULOMATOSIS 71
TABLE 44 EPIDEMIOLOGY FOR WEGENER’S GRANULOMATOSIS 71
7.4.1.3 Antibody-mediated renal transplant rejection 71
7.4.1.3.1 Patient and procedure data for AMR 72
TABLE 45 DISEASE STATISTICS: ANTIBODY?MEDIATED REJECTION 72
TABLE 46 TREATMENT GUIDELINES AND PROTOCOLS FOR ANTIBODY?MEDIATED REJECTION 72
TABLE 47 EPIDEMIOLOGY FOR ANTIBODY?MEDIATED REJECTION 72
7.5 METABOLIC DISORDERS 73
7.5.1 INCREASING ADOPTION OF PLASMA EXCHANGE FOR DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH 73
7.5.1.1 Familial hypercholesterolemia (homozygous) 73
7.5.1.1.1 Patient and procedure data for homozygous familial hypercholesterolemia 73
TABLE 48 DISEASE STATISTICS: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 73
TABLE 49 TREATMENT GUIDELINES AND PROTOCOLS FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 74
TABLE 50 EPIDEMIOLOGY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 74
7.6 OTHER INDICATIONS 74
?

8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER 75
8.1 INTRODUCTION 76
FIGURE 17 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD 76
TABLE 51 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER,
2018–2025 (USD MILLION) 76
8.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS 77
8.2.1 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS ARE THE LARGEST END USERS OF THERAPEUTIC PLASMA EXCHANGE 77
FIGURE 18 NUMBER OF ANNUAL PLASMA DONATIONS IN THE US,
2003?2016 (MILLION) 77
8.3 HOSPITALS & TRANSFUSION CENTERS 78
8.3.1 HOSPITALS & TRANSFUSION CENTERS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 78
8.4 OTHER END USERS 78

9 COMPETITIVE LANDSCAPE 79
9.1 OVERVIEW 79
FIGURE 19 KEY DEVELOPMENTS IN THE US THERAPEUTIC PLASMA EXCHANGE MARKET, JANUARY 2017?JULY 2020 79
9.2 MARKET EVALUATION FRAMEWORK 80
FIGURE 20 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES & APPROVALS WERE THE MOST WIDELY ADOPTED STRATEGIES 80
9.3 COMPETITIVE SITUATIONS AND TRENDS 80
9.3.1 PRODUCT LAUNCHES & APPROVALS 80
9.3.2 EXPANSIONS 81
9.3.3 ACQUISITIONS 82
9.3.4 COLLABORATIONS 82

10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 83
10.1 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY 83
10.2 COMPETITIVE LEADERSHIP MAPPING 83
10.2.1 STARS 83
10.2.2 EMERGING LEADERS 83
10.2.3 PERVASIVE 84
10.2.4 EMERGING COMPANIES 84
FIGURE 21 US THERAPEUTIC PLASMA EXCHANGE MARKET: COMPETITIVE LEADERSHIP MAPPING (2019) 84
10.3 MARKET SHARE ANALYSIS 85
FIGURE 22 US THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY PLAYER, 2019 85
?
10.4 COMPANY PROFILES 87
(Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View)*
10.4.1 TERUMO BCT, INC. 87
FIGURE 23 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018) 87
10.4.2 FRESENIUS SE & CO. KGAA 90
FIGURE 24 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019) 90
FIGURE 25 FRESENIUS KABI: COMPANY SNAPSHOT (2019) 91
10.4.3 HAEMONETICS CORPORATION 94
FIGURE 26 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2020) 94
10.4.4 BAXTER INTERNATIONAL INC. 97
FIGURE 27 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2019) 97
10.4.5 ASAHI KASEI MEDICAL CO. LTD. 100
FIGURE 28 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019) 100
10.4.6 B. BRAUN MELSUNGEN AG 103
FIGURE 29 B. BRAUN MELSUNGEN: COMPANY SNAPSHOT (2019) 103
10.4.7 CERUS CORPORATION 105
FIGURE 30 CERUS CORPORATION: COMPANY SNAPSHOT (2019) 105
10.4.8 KANEKA CORPORATION 107
FIGURE 31 KANEKA CORPORATION: COMPANY SNAPSHOT (2019) 107
10.4.9 KAWASUMI LABORATORIES, INC. 109
FIGURE 32 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019) 109
10.4.10 NIKKISO CO., LTD. 110
FIGURE 33 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2019) 110
10.4.11 MILTENYI BIOTEC 112
10.4.12 MEDICA S.P.A. 113
10.4.13 MEDICAP CLINIC GMBH 114
10.4.14 INFOMED 115
*Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View might not be captured in case of unlisted companies.

11 APPENDIX 116
11.1 INSIGHTS OF INDUSTRY EXPERTS 116
11.2 DISCUSSION GUIDE 117
11.3 KNOWLEDGE STORE 120
11.4 AVAILABLE CUSTOMIZATIONS 122
11.5 RELATED REPORTS 122
11.6 AUTHOR DETAILS 123